MAPT and Alzheimer disease: As reported in Figure 5, a low expression of CX3CL1 was observed in AD subjects (Aβ+Tau and Aβ-Tau) compared to controls and non-AD subjects while a higher expression of P38 was observed in AD subjects, especially in those treated with CSF from patients Aβ-Tau, also, but with lower evidence in the Aβ+Tau group.